
GlaxoSmithKline has posted a third quarter loss after sales of its troubled diabetes drug Avandia and pandemic influenza products fell. …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

